- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02898805
Effects of LopiGLIK® on Cardiovascular Risk (LopiWEB)
Effects of a New Combination of Nutraceutics (LopiGLIK®) on Cardiovascular Risk
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The experimental design involves the construction of a multi-center, controlled, randomized, single-blind, versus Armolipid Plus®.
Patients with mild hypercholesterolemia, of both sexes and aged between 18 and 75 years, will be recruited, from the beginning of the study and for the next 2 weeks, from 30 Cv specialists and/or GPs (25 patients each).
The subjects will be enrolled in the 50/50% male/female ratio ± 10% comparable for age, in order to obtain a proper comparison between groups with similar demographic characteristics or not statistically different.
The subjects, selected on the basis of inclusion and exclusion criteria, will be divided into two groups, subjected to centralized randomization at the "Diagnosis and Treatment of hypertension Center" to receive one of two different treatments, a tablet/day of the new nutraceutical LopiGLIK® (Akademy Pharma) containing Morus Alba, immediately after a meal, vs. a tablet/day of Armolipid Plus, always immediately after the meal. During the first two weeks both groups will follow the prescribed diet and assume the placebo. At the end, blood tests (traditional metabolic parameters, blood glucose, HbA1C, fasting insulin, transaminase levels, CPK) and the endothelial function will be assesed. During the next 16 weeks a group will assume LopiGLIK® (Akademy Pharma) containing Morus Alba, the other will assume Armolipid Plus and everyone will continue to follow the prescribed diet. At the end of this period blood tests will be repeated. Tablets of Armolipid Plus, LopiGLIK® and placebo will be provided by Akademy Pharma free of charge
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Naples, Italy, 80131
- Federico II University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Total Cholesterol<300 mg/dL
- Total Cholesterol>200 mg/dL
- Cardiovascular Risk<20%
Exclusion Criteria:
- Pregnancy
- Documented intolerance to one or more 'components LOPIGLIK / Armolipid PLUS
- Previous cardiovascular events
- Familiar severe dyslipidemia
- Familiar high cardiovascular risk Hepatic or muscular disorders Subjects receiving lipid-lowering drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LopiGLIK®
first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet
|
|
Active Comparator: Armolipid Plus
first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction of LDL-Cholesterol levels
Time Frame: 16 weeks
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Increasing of HDL-Cholesterol levels
Time Frame: 16 weeks
|
16 weeks
|
Reduction of HbA1c levels
Time Frame: 16 weeks
|
16 weeks
|
Reduction of fastin insuline levels
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Trimarco V, Izzo R, Stabile E, Rozza F, Santoro M, Manzi MV, Serino F, Schiattarella GG, Esposito G, Trimarco B. Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. High Blood Press Cardiovasc Prev. 2015 Jun;22(2):149-54. doi: 10.1007/s40292-015-0087-2. Epub 2015 Apr 14.
- Carrizzo A, Ambrosio M, Damato A, Madonna M, Storto M, Capocci L, Campiglia P, Sommella E, Trimarco V, Rozza F, Izzo R, Puca AA, Vecchione C. Morus alba extract modulates blood pressure homeostasis through eNOS signaling. Mol Nutr Food Res. 2016 Oct;60(10):2304-2311. doi: 10.1002/mnfr.201600233. Epub 2016 Jun 27.
- Manfrin A, Trimarco V, Manzi MV, Rozza F, Izzo R. A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK(R)) lowering cardiovascular disease risk. Clinicoecon Outcomes Res. 2018 Oct 8;10:601-609. doi: 10.2147/CEOR.S172838. eCollection 2018.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- AKP_3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Risk Factors
-
Fundacio d'Investigacio en Atencio Primaria Jordi...SCMFIC FAMILY DOCTORS CATALAN SOCIETY GRANTCompletedCardiovascular Risk FactorsSpain
-
Hypertension Excellence Centre LucerneRecruiting
-
Kuwait Institute for Medical SpecializationPfizerUnknownCardiovascular Risk Factors
-
University of OxfordBritish Heart Foundation; European Commission; Oxford University Hospitals NHS... and other collaboratorsRecruitingCardiovascular Diseases | Cardiovascular Risk FactorsUnited Kingdom, Germany, Belgium, China, United States, Australia, France, Greece, Hungary, Italy, Japan, Korea, Republic of, Netherlands, Romania, United Arab Emirates
-
Instituto Mexicano del Seguro SocialUniversity of California, Los Angeles; National Council of Science and Technology...CompletedCardiovascular Risk FactorsMexico
-
Milton S. Hershey Medical CenterTerminated
-
University of MichiganNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCardiovascular Risk FactorsUnited States
-
University of British ColumbiaHopeLab Foundation; Social Sciences and Humanities Research Council of Canada; William T. Grant FoundationCompleted
-
Elvir SASBioFortisCompletedCardiovascular Risk FactorsFrance
-
University of MonastirCompletedCardiovascular Risk Factors | FastingTunisia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States